NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
P/E ratio for NeuroPace, Inc. (NPCE)
P/E ratio as of 2023: -8.09
According to NeuroPace, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.09. At the end of 2022 the company had a P/E ratio of -0.69.
P/E ratio history for NeuroPace, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -8.09 |
| 2022 | -0.69 |
| 2021 | -6.47 |
| 2020 | -16.53 |
| 2019 | -14.60 |